We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Recently, CDE official website showed that the clinical trial application of Betta Pharmaceuticals for BPI-23314 tablets, a type 1 new drug, has been given the implied license.